Press Releases
Press releases from hepCoalition and partner organizations.
Materials in this section
Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!
16 April 2016
People with HCV and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. More
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
On the eve of Gilead’s annual shareholder meeting, thousands of activists have demanded that Gilead change its policies that deny access to treatment for millions in developing countries. More
AIDS 2014: Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
"HCV drugs are priced out of reach and out of control", Michel Sidibé, UNAIDS
Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C drug. More
Today New Hepatitis Resolution is Passed at World Health Assembly; Challenges WHO and Member States to Act
Press Release – 22 May 2014 – Geneva
The World Health Assembly passed new Hepatitis Resolution committing WHO and UN member states to urgent action to address the global hepatitis pandemic. More
International Liver Conference: Activists Demand Affordable Hepatitis C Treatment
Pills cost pennies, greed costs lives.
As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in LMICs. More
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
Bangkok, Thailand, 28 February 2014
Activists from 22 countries joined forces at the first-ever HCV World CAB to demand equitable access to HCV treatment from six multinational pharmaceutical companies. More
First Hepatitis C World Community Advisory Board Meeting
The meeting is to gather 40 international activists to strategize together in order to increase HCV treatment access by addressing key issues. More
Gilead’s HCV Drug Sofosbuvir Approved by the FDA but Accessible for How Many?
Press Release – 9 December 2013 / Bangkok – Paris – Basel – London – New York
On 6 Dec 2013, FDA approved Gilead’s HCV drug Sovaldi. Yet its anticipated price tag of $80,000 will ensure this drug remains out of reach for the vast majority of people with HCV. More
The Time Bomb Is Ticking... Defuse Hepatitis C, the Viral Time Bomb!
Press Release — 25 July 2013
On World Hepatitis Day, millions of people with HCV and their advocates have issued a petition calling on Dr. Margaret Chan to act urgently to increase global access to HCV tools. More